NCT05601310

Brief Summary

This study is a retrospective case-control study. In this study, through untargeted metabolomics, investigators identified several specific changed serum metabolites in T2DM patients with or without AMI and their functions/category. Moreover, researchers selected several endogenous candidate biomarkers with larger fold change for validation in expanded population to find biomarkers which effectively predict the development of STEMI in patients with T2DM.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
82

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2017

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 23, 2017

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 28, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 28, 2020

Completed
2.4 years until next milestone

First Submitted

Initial submission to the registry

October 18, 2022

Completed
14 days until next milestone

First Posted

Study publicly available on registry

November 1, 2022

Completed
Last Updated

November 1, 2022

Status Verified

October 1, 2022

Enrollment Period

3 years

First QC Date

October 18, 2022

Last Update Submit

October 26, 2022

Conditions

Keywords

STEMIMetabolomicsBiomarkersType 2 Diabetes Mellitus

Outcome Measures

Primary Outcomes (1)

  • There are differences in the metabolic profile of diabetic patients with or without combined acute myocardial infarction

    About 10ml of venous blood was collected on the admission, serum was separated. To obtain a complete metabolic profile, untargeted metabolomics analysis was conducted by using UPLC-MS.

    December 16th, 2020

Study Arms (3)

Control group

in the group, the participants exhibited negative results or \<50% obstruction upon coronary artery CT or coronary angiography. The group did not have coronary heart disease and diabetes

Device: liquid chromatography-mass spectrometry (LC/MS) analysis

T2DM group

in the group, the participants exhibited negative results or \<50% obstruction upon coronary artery CT or coronary angiography. The group did not have coronary heart disease but have type 2 diabetes mellitus.

Device: liquid chromatography-mass spectrometry (LC/MS) analysis

T2DM+AMI group

In the group, we eventually recruited 30 adult patients who were firstly diagnosed ST-elevation myocardial infarction (STEMI) within 12 hours of appearance chest pains or other AMI symptoms and had no previous history of coronary artery disease (CAD). Peripheral venous blood samples were drawn from subjects on admission or prior to coronary revascularization.

Device: liquid chromatography-mass spectrometry (LC/MS) analysis

Interventions

To obtain a complete metabolic profile, untargeted metabolomics analysis was conducted by using UPLC-MS. Chromatographic separation was accomplished in an Thermo Vanquish system equipped with an ACQUITY UPLC®HSS T3 (150×2.1 mm, 1.8 µm, Waters, USA) column maintained at 40 ℃. The temperature of the autosampler was 8 ℃. The ESI-MSn experiments were executed on the Thermo Q Exactive mass spectrometer with the spray voltage of 3.5 kV and -2.5 kV in positive and negative modes, respectively. The capillary temperature was 325℃. The analyzer scanned over a mass range of m/z 81-1 000 for full scan at a mass resolution of 70 000. The normalized collision energy was 30 eV(19606840). The detected ions were all under isotopic calibration with the accurate masses of the reference standards.

Control groupT2DM groupT2DM+AMI group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

① Patients with acute ST-segment elevation myocardial infarction (STEMI) who underwent emergency PCI in Beijing Friendship Hospital (Xicheng District) affiliated to Capital Medical University. ②In the Beijing Friendship Hospital (Xicheng District) affiliated to Capital Medical University, coronary angiography showed negative coronary angiography or coronary artery CT showed \<50% obstruction in patients with non-coronary heart disease.

You may qualify if:

  • STEMI patients meet the diagnostic criteria of "Guidelines for the Diagnosis and Treatment of Acute ST-segment Elevation Myocardial Infarction (2015)".
  • STMEI patients undergoing emergency PCI should undergo emergency PCI within 12 hours of onset at Beijing Friendship Hospital affiliated to Capital Medical University.
  • All diabetic patients meet the diagnostic criteria for type 2 diabetes.
  • They agreed to be enrolled in the trial and signed the informed consent.

You may not qualify if:

  • Combined with severe valvular disease or congenital heart disease, hypertension, chronic kidney disease, stroke, hyperlipidemia, previous history of coronary artery disease.
  • Involved in acute infection, severe hepatic dysfunction, tumor, rheumatic immune disease.
  • Incomplete clinical information.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Weiping Li

Beijing, Beijing Municipality, 100032, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum

MeSH Terms

Conditions

ST Elevation Myocardial InfarctionDiabetes Mellitus, Type 2

Interventions

Liquid Chromatography-Mass Spectrometry

Condition Hierarchy (Ancestors)

Myocardial InfarctionMyocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosisDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Chromatography, LiquidChromatographyChemistry Techniques, AnalyticalInvestigative TechniquesMass Spectrometry

Study Officials

  • Weiping Li, MD

    Beijing Friendship Hospital

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
chief physician

Study Record Dates

First Submitted

October 18, 2022

First Posted

November 1, 2022

Study Start

May 23, 2017

Primary Completion

May 28, 2020

Study Completion

May 28, 2020

Last Updated

November 1, 2022

Record last verified: 2022-10

Data Sharing

IPD Sharing
Will not share

Locations